Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial

Beta Agonist ◽

Inhaled Corticosteroid ◽

Step Down ◽

Faculty Opinions recommendation of Randomized clinical trial of a combination of an inhaled corticosteroid and beta agonist in patients at risk of developing the acute respiratory distress syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727348815.793567309 ◽

2019 ◽

Author(s):

Kathryn Anne Hibbert

Keyword(s):

Clinical Trial ◽

At Risk ◽

Acute Respiratory Distress Syndrome ◽

Respiratory Distress Syndrome ◽

Respiratory Distress ◽

Distress Syndrome ◽

Beta Agonist ◽

Inhaled Corticosteroid ◽

Patients At Risk

Serious Asthma Outcomes and Asthma Exacerbations with Maintenance on Inhaled Corticosteroid (Mometasone Furoate)/Long-Acting Beta Agonist (Formoterol) Combination Compared to Step Down to Mometasone Monotherapy

The Journal of Allergy and Clinical Immunology In Practice ◽

10.1016/j.jaip.2020.01.021 ◽

2020 ◽

Vol 8 (5) ◽

pp. 1634-1644.e1

Author(s):

Cindy L.J. Weinstein ◽

Nicholas Ryan ◽

Xiaoli Zhang ◽

Tulin Shekar ◽

Davis Gates ◽

...

Keyword(s):

Mometasone Furoate ◽

Beta Agonist ◽

Inhaled Corticosteroid ◽

Asthma Exacerbations ◽

Asthma Outcomes ◽

Step Down ◽

Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE2SPOND). A Randomized Clinical Trial

American Journal of Respiratory and Critical Care Medicine ◽

10.1164/rccm.201607-1349oc ◽

2016 ◽

Vol 194 (5) ◽

pp. 559-567 ◽

Cited By ~ 63

Author(s):

Fernando J. Martinez ◽

Klaus F. Rabe ◽

Sanjay Sethi ◽

Emilio Pizzichini ◽

Andrew McIvor ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Clinical Trial ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

Long Acting ◽

Β2 Agonist

Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome*

Critical Care Medicine ◽

10.1097/ccm.0000000000002284 ◽

2017 ◽

Vol 45 (5) ◽

pp. 798-805 ◽

Cited By ~ 22

Author(s):

Emir Festic ◽

Gordon E. Carr ◽

Rodrigo Cartin-Ceba ◽

Richard F. Hinds ◽

Valerie Banner-Goodspeed ◽

...

Keyword(s):

Clinical Trial ◽

At Risk ◽

Acute Respiratory Distress Syndrome ◽

Respiratory Distress Syndrome ◽

Respiratory Distress ◽

Distress Syndrome ◽

Beta Agonist ◽

Inhaled Corticosteroid ◽

Patients At Risk

Faculty Opinions recommendation of Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726702469.793522876 ◽

2016 ◽

Author(s):

David Halpin

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Clinical Trial ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

Long Acting ◽

Β2 Agonist

Exacerbations of asthma following step-up and step-down inhaled corticosteroid and long acting beta agonist therapy in the managing asthma in pregnancy study

Journal of Asthma ◽

10.1080/02770903.2020.1847934 ◽

2020 ◽

pp. 1-8

Author(s):

Vanessa E. Murphy ◽

Megan E. Jensen ◽

Peter G. Gibson

Keyword(s):

Beta Agonist ◽

Inhaled Corticosteroid ◽

Agonist Therapy ◽

Step Down ◽

Long Acting ◽

In Pregnancy

Faculty Opinions recommendation of Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725585522.793511377 ◽

2015 ◽

Author(s):

Steven Potkin ◽

Adrian Preda

Keyword(s):

Clinical Trial ◽

Relapse Prevention ◽

Prevention And Control ◽

First Episode ◽

Long Acting ◽

And Control ◽

First Episode Of Schizophrenia

Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year

Clinical Drug Investigation ◽

10.1007/s40261-021-01067-w ◽

2021 ◽

Author(s):

Pier Paolo Mangia ◽

Ottavio Gallo ◽

Daniela Ritrovato ◽

Lorenzo Pradelli

Keyword(s):

Cost Utility ◽

Beta Agonist ◽

Fixed Dose ◽

High Dose ◽

Inhaled Corticosteroid ◽

Utility Analysis ◽

Glycopyrronium Bromide ◽

Asthma Exacerbations ◽

Dose Combination ◽

In adults with mild persistent asthma, is as-needed use of a combined inhaled corticosteroid plus long-acting beta-agonist as effective as scheduled use of an inhaled corticosteroid alone in preventing asthma exacerbations?

Evidence-Based Practice ◽

10.1097/ebp.0000000000001292 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Vishalakshi Sundaram ◽

Linda Wei Zhang ◽

Paige Gwynn

Keyword(s):

Persistent Asthma ◽

Beta Agonist ◽

Inhaled Corticosteroid ◽

Asthma Exacerbations ◽

Mild Persistent Asthma ◽

Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis

Respirology ◽

10.1111/resp.12603 ◽

2015 ◽

Vol 20 (8) ◽

pp. 1153-1159 ◽

Cited By ~ 19

Author(s):

Nobuyuki Horita ◽

Naoki Miyazawa ◽

Koji Tomaru ◽

Miyo Inoue ◽

Takeshi Kaneko

Keyword(s):

Systematic Review ◽

Meta Analysis ◽

Beta Agonist ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽